Compare LEU & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEU | ANAB |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 1.4B |
| IPO Year | 1998 | 2017 |
| Metric | LEU | ANAB |
|---|---|---|
| Price | $248.98 | $48.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $243.00 | $59.90 |
| AVG Volume (30 Days) | ★ 875.0K | 433.4K |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 6.17 | N/A |
| Revenue | ★ $454,100,000.00 | $169,467,000.00 |
| Revenue This Year | $1.17 | $135.45 |
| Revenue Next Year | $8.96 | N/A |
| P/E Ratio | $40.40 | ★ N/A |
| Revenue Growth | 15.25 | ★ 196.42 |
| 52 Week Low | $49.40 | $12.21 |
| 52 Week High | $464.25 | $52.47 |
| Indicator | LEU | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 60.39 |
| Support Level | $244.38 | $49.50 |
| Resistance Level | $263.73 | $52.47 |
| Average True Range (ATR) | 19.48 | 2.34 |
| MACD | 2.29 | -0.04 |
| Stochastic Oscillator | 47.05 | 47.01 |
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).